



NEUROSOME



H2020-MSCA-ITN-2017 GA - 766251

Heraklion, Crete, May 2019

NEUROSOME: First training event

# NEUROSOME

## Exploring The Neurological Exposome

# Computational methods in toxicology

**Denis A. Sarigiannis, PhD<sup>1,2,3</sup>, Spyros Karakitsios<sup>1,2</sup>**

<sup>1</sup>*Aristotle University of Thessaloniki, Department of Chemical Engineering, Environmental Engineering Laboratory, University Campus, Thessaloniki 54124, Greece*

<sup>2</sup>*HERACLES Research Center on the Exposome and Health, Center for Interdisciplinary Research and Innovation, Balkan Center, Bldg. B, 10th km Thessaloniki-Thermi Road, 57001, Greece*

<sup>3</sup>*School for Advanced Study (IUSS), Science, Technology and Society Department, Environmental Health Engineering, Piazza della Vittoria 15, Pavia 27100, Italy*

**<http://www.enve-lab.eu>**

This project has received funding from the European Union's H2020 Framework Programme under grant agreement No - GA - 766251



NEUROSOME



# Connectivity-based workflow for exposome studies



H2020-MSCA-ITN-2017 GA - 766251

Heraklion, Crete, May 2019

NEUROSOME: First training event






# The need for *in-silico* approaches **Risk assessment of chemicals**



*“anything that we can do with a computer in toxicology”*






*“integration of modern computing and information technology with molecular biology to improve agency prioritization of data requirements and risk assessment of chemicals”*

## Risk assessment of chemicals

Need for better mechanistic data

- Determine human relevance
- What is the relevant Mode of Action (MOA) or Adverse Outcome Pathway (AOP)?





NEUROSOME



H2020-MSCA-ITN-2017 GA - 766251

Heraklion, Crete, May 2019

NEUROSOME: First training event


# Bioinformatics for multi-omics





## - Introduction to "omics"

- Metabolomics
- Metabonomics
- Transcriptomics
- Genomics
- Proteomics
- Bionomics
- Toxicogenomics
- And many more





# But what is "omics"?



- A useful concept in biology which informally annotates a field of study ending in '-omics'. **Omics** aims at the collective characterization and quantification of pools of biological molecules that translate into the structure, dynamics and function, of an organism
- "Omics is a general term for a broad discipline of science and engineering for analyzing the interactions of biological information objects in various 'omes'. [...] The main focus is on: 1) mapping information objects such as genes, proteins, and ligands; 2) finding interaction relationships among the objects; 3) engineering the networks and objects to understand and manipulate the regulatory mechanisms; and 4) integrating various omes and omics subfields."




Image Source: Goodacre, J. Exp. Bot 2005.





Image Source:  
<http://fluorous.com/images/omics.JPG>





# Pathway Analysis Workflow






# Pathway Analysis-SEA




To start a SEA follow the pathway:  
Workflow → Pathway Analysis → Single  
Experiment Analysis



Choose pathway  
databases

Choose annotations





# Pathway Analysis-SEA Results



Mass Profiler Professional - MPP - PA - EXAMPLE

Project Navigator: AUTH\_REPLO\_PL\_URINESAMPLES.x

URINE EXAMPLE

methythiopropionate biosynthesis - Homo sapiens

EXAMPLE		
Interpretation	All Samples	
Entity List	All Entities	
Pathway	Matched Entities...	Pathway Entities ...
methythiopropionate biosynthesis	1	6
zymosterol biosynthesis	1	22
NAD phosphorylation and dephosphorylation	2	9
fatty acid Alpha-oxidation II	4	14
tryptophan degradation III (eukaryotic)	2	28
superpathway of serine and glycine biosynthesis I	3	14
pyruvate fermentation to lactate	2	5
fatty acid activation	2	6
folate polyglutamylation	6	12
tyrosine biosynthesis IV	1	5
selenocysteine biosynthesis II (archaea and eukary...	4	10
proline biosynthesis I	4	14
L-dopa degradation	1	12
leukotriene biosynthesis	2	13
sphingosine and sphingosine-1-phosphate metab...	2	14
tryptophan degradation to 2-amino-3-carboxym...	2	13
lactose degradation III	1	4
ceramide degradation	2	8
choline biosynthesis III	2	11
nicotinenogenesis I	4	73

Find:  Find Next Find Previous Match Case

Show EXAMPLE

Min # of matches:

Workflow:

- Experiment Setup
  - Quick Start Guide
  - Experiment Grouping
  - Create Interpretation
- Quality Control
- Analysis
- Class Prediction
- Results Interpretati...
- Pathway Analysis
  - Single Experiment Analysis
  - Multi-Omic Analysis
  - Launch IPA
  - Export to MetaCore
  - Connect to Cytoscape
- NLP Networks
- Utilities

Legend: Legend - SEA-All Entite

Heatmap Quit Plots Layout Color

Color Range for EXAMPLE



-6.6 -0.7 5.2

Spreadsheet (Log2 Normalized) SEA-All Entities - Pathway View x

366M of 938M



- **Urine** and **cord blood** samples of pregnant women exposed to environmental contaminants (phthalates, Pb, Hg)
  - Urinary concentrations of phthalates
  - Cord blood Pb
  - Hair Hg
- EWAS analysis
- LC MS/MS (Thermo Orbitrap) for metabolites identification
- NMR (Agilent 600MHz)
- Agilent Genespring / Mass Profiler Pro for pathway identification









NEUROSOME


# Heatmap



H2020-MSCA-ITN-2017 GA - 766251

Heraklion, Crete, May 2019

NEUROSOME: First training event









NEUROSOME

# Volcano Plot


## Cognitive development




H2020-MSCA-ITN-2017 GA - 766251

NEUROSOME: First training event

Heraklion, Crete, May 2019



1<sup>st</sup> year  
year



2<sup>nd</sup>



	BSID.III_cog1
Effects of Nitric Oxide	+
Thiobarbituric acid reactive substances (TBARS_20.24_week)	+
Cu 8-12 week	+
Attendance to day care school during the 2st year after birth	+
Gestational age	-
Inosine 5 phosphate biosynthesis II	-
Asparagine degradation I	-
Citrulline nitric oxide cycle	-
Urea cycle	-

	BSID.III_cog2
Zn 8-12 week	+
Superoxide Dismutase-SOD 30-34 week	-






	BSID.III_lan1
Glutathione Peroxide-GPx3 8-12_ week	+
Glutathione Peroxide-GPx3 20-24 week	+
Glutathione Peroxide-GPx3 30-34 week	+
Glutathione Peroxide-GPx3 mothers at delivery	+
SOD 30-34 week	+
Thiobarbituric acid reactive substances (TBARS_8.12_week)	+
GPx1 cord blood	-

	BSID.III_lan2
Oxobutanoate degradation I	+
Cysteine biosynthesis/homocysteine degradation	+
Glycolysis/Gluconeogenesis	+
Drug Induction of Bile Acid Pathway	+
Attendance to day care school during the 1st year after birth	+
Zn 8-12 week	+
Superoxide Dismutase-SOD 30-34 week	-




# Volcano Plot

## Motor development



1<sup>st</sup> year  
year



2<sup>nd</sup>



# Volcano Plot

## Motor development




	BSID.III_mot1
Lysine degradation II	+
Se delivery	-

	BSID.III_mot2
purine ribonucleosides degradation to ribose 1 phosphate	+
Attendance to day care school during the 1st year after birth	+
Zn 8-12 week	+
Superoxide Dismutase-SOD 30-34 week	-



# Network analysis



**Fig. Undirected community network. Cluster on the correlation results of EWAS analysis.**



# Pathway identification






Figure 46 Serine, Threonine and Glycine metabolism (KEGG)





# Pathway identification Hg and Pb





NEUROSOME



H2020-MSCA-ITN-2017 GA - 766251

Heraklion, Crete, May 2019

NEUROSOME: First training event



# Biokinetics




# The need for *in-silico* approaches



Environmental stressors





Human exposure




PBPK modelling



Community Effects / Cohorts



Human biosampling




Dose

*In vitro*



Bioinformatics / Systems biology / AOPs



Multi-omics



NEUROSOME

# Development of generic multi-route lifetime PBPK model



H2020-MSCA-ITN-2017 GA - 766251

NEUROSOME: First training event

Heraklion, Crete, May 2019

## PBPK models serve three main purposes:

- *internal dose assessment (I)*
- *to provide the framework for exposure reconstruction (III)*
- *to derive Biomonitoring Equivalents (BEs) for risk characterization (III)*



# Development of generic multi-route lifetime PBPK model



PBPK models are modeling tools that describe the mechanisms of absorption, distribution, metabolism and elimination (ADME) of chemicals in the body resulting from acute and/or chronic exposure regimes. Within the boundary of the identified compartment (e.g., an organ or tissue or a group of organs or tissues), whatever inflows must be accounted for via whatever outflows or whatever is transformed into something else.

This mass balance is expressed as a mathematical equation with appropriate parameters carrying biological significance. A generic equation, for any tissue or organ, is:

$$V_i \frac{dC_{ij}}{dt} = Q_i (CA_j - CV_{ij}) - Metab_{ij} - Elim_{ij} + Absorp_{ij} - Pr Binding_{ij}$$





# Development of generic multi-route lifetime PBPK model



$$V_i \frac{dC_{ij}}{dt} = Q_i (CA_j - CV_{ij}) - Metab_{ij} - Elim_{ij} + Absorp_{ij} - Pr Binding_{ij}$$

Where:

$V_i$  represents the volume of tissue group  $i$ ,

$Q_i$  is the blood flow rate to tissue group  $i$ ,

$CA_j$  is the concentration of chemical  $j$  in arterial blood, and

$C_{ij}$  and  $CV_{ij}$  are the concentrations of chemical  $j$  in tissue group  $i$  and in the effluent venous blood from tissue  $i$ , respectively.

$Metab_{ij}$  is the rate of metabolism for chemical  $j$  in tissue group  $i$ ; liver, being the principal organ for metabolism would have significant metabolism and, with some exception, usually  $Metab_{ij}$  is equal to zero in other tissue groups.

$Elim_{ij}$  represents the rate of elimination from tissue group  $i$  (e.g., biliary excretion from the liver),

$Absorp_{ij}$  represents uptake of the chemical from dosing (e.g., oral dosing)

$PrBinding_{ij}$  represents protein binding of the chemical in the tissue. All these terms are zero unless there is definitive knowledge that the particular organ and tissue of interest has such processes.



NEUROSOME


# Development of generic multi-route lifetime PBPK model



H2020-MSCA-ITN-2017 GA - 766251

NEUROSOME: First training event

Heraklion, Crete, May 2019





# Development of generic multi-route lifetime PBPK model



NEUROSOME: First training event

Organ volumes ( $V$ ) and blood flows ( $Q$ ) were taken from the ICRP (2002) report and the obtained data were fitted to time ( $T$ ) in order to exclude continuous time dependent non-linear polynomial formulas in the form of:

$$V = a \cdot T^b + c \cdot T^d + e$$


The permeability parameters PS were scaled according to the formula:

$$PS_{tissue\_child} = PS_{tissue\_adult} \left( \frac{V_{tissue\_child}}{V_{tissue\_adult}} \right)^{0.75}$$

Age dependent clearance:

$$CL_{INT} = \alpha_{ontogeny} \cdot CL_H \frac{Q_H}{Q_H - CL_H} \cdot \frac{1}{f_u}$$

where  $Q_H$  is the hepatic blood flow,  $CL_H$  is the plasma clearance,  $CL_{INT}$  is the intrinsic hepatic clearance per gram of liver weight and  $f_u$  is the fraction unbound in plasma,  $\alpha_{ontogeny}$  is an ontogeny factor that represents the activity of the specific enzyme in relation to the age



## Breast feeding link

$$V \frac{dC_{breast}}{dt} = PS_{cell\_breast} \cdot fu \cdot \left( C_{int\_breast} - \frac{C_{breast}}{K_{breast}} \right) - L_{excr}$$

$$L_{excr} = Q_{milk} \cdot \frac{C_{breast}}{K_{breast}} \cdot P_{milk/blood}$$

$$P_{milk/blood} = \frac{K_{ow} \cdot FL_{tissue} + FW_{tissue}}{K_{ow} \cdot FL_{blood} + FW_{blood}}$$

## Mother – Fetus interaction



$$\frac{\partial Q_{uterus\_M}}{\partial t} = F_{uterus\_M} \times \left( C_{art\_M} - \frac{C_{uterus\_M}}{P_{uterus}} \right) - K_{d\_uter\_pla} \times (C_{placenta} - C_{uterus\_M})$$

$$\frac{\partial Q_{placenta}}{\partial t} = K_{d\_uter\_pla} \times (C_{placenta} - C_{uterus\_M}) + F_{placenta\_B} \times \left( C_{art\_B} - \frac{C_{placenta}}{P_{placenta}} \right) - K_{d\_pla\_amniot} \times \left( C_{placenta} - C_{amniot} \frac{P_{placenta}}{P_{amniot}} \right) - K_{m\_placenta} \times C_{placenta}$$

$$\frac{\partial Q_{amniot}}{\partial t} = K_{d\_pla\_amniot} \times \left( C_{placenta} - C_{amniot} \frac{P_{placenta}}{P_{amniot}} \right) + K_{e\_gut\_B} \times C_{gut\_B} + K_{e\_bile\_B} \times C_{liver\_B} - K_{a\_amniot\_B} \times C_{amniot}$$




# Skin Structure and PBPK modelling









# Skin Structure and PBPK modelling






# Skin Structure and PBPK modelling




$$t = 1 + \frac{2g}{h} \ln\left(\frac{d}{2s}\right) + \frac{N \cdot d \cdot t}{s \cdot h} + \left(\frac{d}{1+\omega}\right)^2 \frac{\omega \cdot (N-1)}{h \cdot g}$$



Description	Symbol	Value	Unit
Number of layer	N	15	-
Length of corneocyte	d	30	um
Thickness of corneocyte	t	10	um
Length of path 1	d <sub>1</sub>	20	um
Length of path 2	d <sub>2</sub>	10	um
Vertical gaps	s	0,03	um
Horizontal gaps	g	0,03	um
corneocyte edge angle	φ	90°	degrees
Effective Diffusivity f(φ)	D <sub>ef</sub>	0.002	cm <sup>2</sup> /m



## Uncertainty implementation




**Hierarchical population model used in Bayesian analysis (Gelman et al, 1996).**  
**Circles represent distributions and squares/rectangles represent known entities**  
 $\mu$ : prior mean distribution  
 $\Sigma^2$ : prior variance distribution  
 $\theta$ : study level distributions for each of the parameters based on randomly selected values for the mean and variance from the population distributions  $\mu$  and  $\Sigma^2$





# Coupling biokinetics and metabolic regulation






## Exposure Reconstruction Techniques

- **Deterministic Inversion**
- **Stochastic Inversion/Bayesian Approach**
- **Exposure Conversion Factor Approach**
- **Discretized Bayesian Approach**
- **Bayesian Markov Chain Monte Carlo**




# Exposure reconstruction trivial scheme






# Exposure reconstruction







# Chemical mixtures interaction at the level of metabolism



The Effects of Inhibition on Enzyme Kinetics



$$RAM_1 = k_1 \frac{V_{max\_1} \times (S1)}{[S1(T_2) + K_{M1}(T2)]}$$

$$RAM_1 = \frac{V_{max\_1} \cdot S1}{K_{M1} \left( 1 + \frac{S2}{KM_{2-1}} + \dots + \frac{Sn}{KM_{n-1}} \right) + S1}$$



NEUROSOME



H2020-MSCA-ITN-2017 GA - 766251


NEUROSOME: First training event

Heraklion, Crete, May 2019


# QSARs for biokinetic modelling





(A)



(B)









- Literature Review

Algorithms using:

- Tissue Composition [1]
- Group Contribution Method [2]
- Linear Free Energy Relationship [3]

Kidney/blood PC  
Heart/blood PC  
Muscle/blood PC  
Adipose/blood  
PC  
Brain/blood PC  
Lung/blood PC  
Liver/blood PC

- Development of a QSAR model using LFER

Application of the LFER

to address


tissue/blood partition coefficients and  
constants of metabolism

Maximal Velocity of Metabolism,  $V_{max}$   
Michaelis – Menten Constant,  $K_m$


[1] Peyret T, Poulin P, Krishnan K. A unified algorithm for predicting partition coefficients for PBPK modeling of drugs and environmental chemicals. Toxicology and Applied Pharmacology 2010; 249: 197-207.

[2] Gao C, Goind R, Tabak HH. Application of the group contribution method for predicting the toxicity of organic chemicals. Environmental Toxicology and Chemistry 1992; 11: 631-636.

[3] Abraham MH. Application of solvation equations to chemical and biochemical processes. Pure and Applied Chemistry 1993; 65: 2503-2512.



# Overall Approach





## 1. Linear Free – Energy Relationship (LFER)

$$\log SP = c + e \cdot E + s \cdot S + a \cdot A + b \cdot B + v \cdot V$$

SP: biological property of a chemical (tissue/blood partition coefficients and parameters of metabolism)

E: excess molar refractivity of the chemical

S: chemical's dipolarity/polarizability

A: solute effective or summation hydrogen-bond acidity of the chemical

B: solute effective or summation hydrogen-bond basicity of the chemical

V: McGowan characteristic volume of the chemical


c, e, s, a, b, v: constants that reflect the properties of the chemical

## 2. Data collection

- Experimental values of  $P_{\text{tissue/blood}}$  of 33 organic chemicals
- Experimental values of  $V_{\text{maxc}}$  and  $K_m$  of 29 organic chemicals
- Experimental and computed values of molecular descriptors (E, S, A, B, V)

## 3. Statistical Analysis

- **a. Artificial Neural Networks (ANN)**
  - Multi-Layer Perceptron (MLP) model using the scaled conjugate gradient back-propagation algorithm.
  - Input data divided into the training (70%), the validation (15%) and the testing (15%) data.



- **b. Non Linear Regression (NLR)**

- Form of the NLR model:
 
$$y = f(X, \beta) + \varepsilon$$

$\beta$ : constants of LFER (c, e, s, a, b, v)

$\varepsilon$ : error term

- Least Squares (LS) coupled with the Levenberg-Marquardt algorithm.



## 4. Expanding the Domain of Applicability

The QSAR model, derived from ANN analysis, was used:

- for the estimation of tissue/ blood partition coefficients for the main human tissues
  - for several chemical compounds, categorized into chemical families, including **hydrocarbons, aromatic and halogenated hydrocarbons, alcohols, ketones, ethers and esters.**
- The results were validated using the equation:

$$P_{tissue/blood} = \frac{P_{ow} \cdot Fl_{tissue} + P_{ow} \cdot Fw_{tissue}}{P_{ow} \cdot Fl_{blood} + P_{ow} \cdot Fw_{blood}}$$

$P_{ow}$ : octanol/ water partition coefficient,


$Fl_{tissue}$  and  $Fw_{tissue}$ : fractional contents of lipids and water in tissue, respectively, and




$Fl_{blood}$  and  $Fw_{blood}$ : fractional contents of lipids and water in blood, respectively [4].





## Kidney/blood Partition Coefficient





- Predicted Values – ANN
- Predicted Values – NLR
- Literature Data [5 ,6]
- Predicted Values – ANN
- Predicted Values – NLR
- Literature Data





[5] Zhang H. A new nonlinear equation for the tissue/blood partition coefficients of neutral compounds. Journal of Pharmaceutical Sciences 2004; 93: 1595-1604.

[6] Price K, Krishnan K. An integrated QSAR-PBPK modelling approach for predicting the inhalation toxicokinetics of mixtures of volatile organic chemicals in the rat. SAR and QSAR in Environmental Research 2011; 22: 107-128.



# Results

## Tissue/blood Partition Coefficients









# Results

## Tissue/blood Partition Coefficients



$R^2$  for Tissue/blood Partition Coefficients using ANN and NLR












	E	S	A	B	V
log Kidney/blood partition coefficient	15.2	22.0	19.5	13.9	29.4
log Heart/blood partition coefficient	23.0	24.0	7.3	23.7	22.0
log Adipose/blood partition coefficient	10.2	8.3	13.5	28.5	39.5
log Liver/blood partition coefficient	8.9	16.0	31.2	10.1	33.8
log Muscle/blood partition coefficient	16.5	19.9	20.6	9.9	33.1
log Brain/blood partition coefficient	21.6	12.8	19.6	12.7	33.3
log Lung/blood partition coefficient	29.5	11.8	13.3	13.0	32.4
log $V_{max}$	13.3	35.4	22.7	20.2	8.4
log $K_m$	23.5	21.5	11.3	13.6	30.1







## External exposure assessment





# Internal dosimetry aspects of BPA toxicokinetics



- Wider inter-individual variability regarding glucuronidation capacity (significantly lower clearance for neonates/infants)
- Very strong plasma protein binding
- First-pass metabolism decisive for clearance – wide bioavailability differences are expected from routes beyond oral (up to six times higher internal dose concentrations for inhalation compared to oral)
- BPA-GLU de-conjugates to BPA in the stomach, increasing the actual dose during breast feeding, thus, the sum of BPA and BPA-GLU needs to be taken into account as BPA dose during breast feeding
- BPA-GLU de-conjugates to BPA in the placenta, increasing the actual dose during pregnancy



# Internal dosimetry aspects of BPA toxicokinetics



- The EFSA t-TDI of 4  $\mu\text{g}/\text{kg}_{\text{bw}}/\text{d}$  was translated into internal exposure, found to correspond to a concentration of 0.013  $\mu\text{g}/\text{L}$  of free plasma BPA (in adults).
- The use of internal dosimetry metrics allows the use of *in vitro* toxicological data for risk characterization. The ToxCast BPA *in vitro* assays provided six ER agonist or binding AC50 values for BPA, ranging from 0.6 to 1.7  $\mu\text{M}$ . To calculate a conservative Biological Pathway Altering Dose (BPAD), the lowest ToxCast AC50 was selected, which is 0.64  $\mu\text{M}$  for Attagene Factorial cis ERE assay.

Incorporating the uncertainty factors related to population response to xenobiotics, two different values are produced, namely the BPAD99, which is the permissible exposure level that accounts for population variability, and BPADL99, which is the permissible exposure level additionally accounting for uncertainty.


By using the reverse toxicokinetic approach that accounts for the concentration at steady state divided by the dose rate, the respective the estimated population parameters gives a BPAD99 of 0.44  $\mu\text{g}/\text{kg}_{\text{bw}}/\text{d}$ , with lower one-sided confidence limit, BPADL99, of 0.16  $\text{mg}/\text{kg}/\text{day}$ .

Using these external exposure values in our PBTK model, we derive equivalent internal dose of 1.44 and 0.52  $\mu\text{g}/\text{L}$  respectively. These concentrations are almost 2 orders of magnitude higher than the BED derived from the EFSA t-TDI (0.013  $\mu\text{g}/\text{L}$ )<sup>58</sup>




## Translating external reference value into **internal** reference value

### EFSA t-TDI BED in adults



### EFSA t-TDI BED in neonates





NEUROSOME

# External to internal


## Exposure to BPA at EFSA t-TDI (4 µg/kg\_bw/d)



H2020-MSCA-ITN-2017 GA - 766251



NEUROSOME: First training event

Heraklion, Crete, May 2019





## Translating external into **internal** exposure assessment







NEUROSOME


# Mechanism hypothesis



H2020-MSCA-ITN-2017 GA - 766251

NEUROSOME: First training event

Heraklion, Crete, May 2019





NEUROSOME



H2020-MSCA-ITN-2017 GA - 766251

Heraklion, Crete, May 2019


NEUROSOME: First training event

# Exposure reconstruction based on HBM data

- Urinary TCM (morning voids) was measured in 20 matched mothers and children (paired)
- Using the children urinary TCM levels, indoor air background TCM concentrations were reconstructed
- These concentrations were used for estimating mother exposure

↓  
 Urinary TCM was predicted for the paired others (nested reconstruction)

↓  
 Re-running forward the model we estimated TCM blood levels (internal exposure)





NEUROSOME


# Reconstructing exposure from time-dynamic data



H2020-MSCA-ITN-2017 GA - 766251

NEUROSOME: First training event

Heraklion, Crete, May 2019






# Reconstructing exposure from time-dynamic data




## Volunteer H - Triclosan






# Exposure reconstruction





# Exposure reconstruction







NEUROSOME



H2020-MSCA-ITN-2017 GA - 766251

NEUROSOME: First training event

Heraklion, Crete, May 2019

Bertold Brecht's *Life of Galileo*:

*"The main objective of science is not to open the door to infinite wisdom but to roll back the boundaries of infinite error."*

***Thank you for your attention***



[www.enve-lab.eu](http://www.enve-lab.eu)

*A connectivity perspective to environmental health*